United States: FDA's Office Of Prescription Drug Promotion Issues Second Untitled Letter Of The Year To Exeltis For Misleading Statements Relating To SLYND® - Sheppard Mullin Richter & Hampton

United States: FDA's Office Of Prescription Drug Promotion Issues Second Untitled Letter Of The Year To Exeltis For Misleading Statements Relating To SLYND® - Sheppard Mullin Richter & Hampton

Mondaq

Published

On August 11, 2023, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an untitled letter to Exeltis USA Inc. (Exeltis) regarding a promotional...

Full Article